Dow Jones
33.891,02 -34,99 (-0,10%) Nasdaq
11.887,45 -119,50 (-1,00%) Nikkei 225
27.678,87 -14,78 (-0,05%) EUR/USD
1,0741 +0,0010 (+0,10%) BTC-EUR
21.346,95 -19,93 (-0,09%) CMC Crypto 200
526,46 +1,32 (+0,25%)
AIM ImmunoTech Inc. (0A4Y.L)
| Chiusura precedente | 0,6456 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | -0,46 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4040 |
| Prossima data utili | 15 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Research collaboration will evaluate the potential of AIM’s Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancerOCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-C
- GlobeNewswire
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
OCALA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus— today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted a utility patent covering rugged dsRNA, a double-stranded RNA product related
- GlobeNewswire
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
Live video webcast on Wednesday, January 18th at 11:00 AM ETOCALA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced that AIM Chief Executive Officer Thomas K. Equels will present at the Virtual Investor 20
